Effect of MicroRNA-4713-3p on Promoting Malignant Progression of Nasopharyngeal Carcinoma via Targeted Inhibition of EPHX3 to Activate Wnt/β-Catenin Signaling Pathway
- PMID: 40878263
- DOI: 10.1002/jbt.70450
Effect of MicroRNA-4713-3p on Promoting Malignant Progression of Nasopharyngeal Carcinoma via Targeted Inhibition of EPHX3 to Activate Wnt/β-Catenin Signaling Pathway
Abstract
Nasopharyngeal carcinoma (NPC) represents a common malignancy in the head-and-neck region, and its development and prognosis can be influenced by multiple factors. Epoxide hydrolase 3 (EPHX3) is an enzyme that perform crucial roles in inflammation and tumors regulation. We aim to discuss the expression pattern and biological function of EPHX3 in NPC. The EPHX3 expression patterns in NPC tissues and cell lines were determined by the qRT-PCR technique. Correlations between EPHX3 expression and the clinical characteristics of NPC patients were subsequently assessed. Afterwards, the mechanism of miR-4713 targeting EPHX3 in NPC was validated either in vitro or in vivo. Gene set enrichment analysis and cell experiments were conducted to prove the impact of the EPHX3-regulated downstream Wnt/β-catenin pathway on the progression of NPC and epithelial-mesenchymal transition (EMT). EPHX3 mRNA expression was significantly downregulated in NPC tissues compared with adjacent normal tissues (p < 0.01). Overexpression of miR-4713-3p markedly enhanced cell proliferation (p < 0.05), migration, and invasion, while dual-luciferase and molecular docking confirmed that EPHX3 is a direct target of miR-4713-3p. Mechanistically, key components of the Wnt/β-catenin pathway, including β-catenin and c-Myc, were significantly upregulated following miR-4713-3p overexpression (p < 0.01), whereas EPHX3 overexpression suppressed these changes and inhibited EMT. In vivo, miR-4713-3p knockdown suppressed tumor growth in xenograft models (p < 0.05). Our study reveals the significance of EPHX3 in the development of NPC and offers a basis for the promise of EPHX3 as a possible therapeutic target.
Keywords: Wnt/β‐catenin pathway; epithelial‐mesenchymal transition (EMT); epoxide hydrolase 3; miR‐4713; miR‐4713‐3p; nasopharyngeal carcinoma.
© 2025 Wiley Periodicals LLC.
Similar articles
-
CDCP1 promotes the malignant phenotypes of nasopharyngeal carcinoma via the Wnt/β-catenin signaling pathway.BMC Biotechnol. 2025 Jul 7;25(1):67. doi: 10.1186/s12896-025-01001-4. BMC Biotechnol. 2025. PMID: 40624715 Free PMC article.
-
LncRNA ZNF295-AS1 modulates nasopharyngeal carcinoma progression via the miR-762/HDAC6 axis-mediated autophagy.Cell Signal. 2025 Nov;135:112064. doi: 10.1016/j.cellsig.2025.112064. Epub 2025 Aug 14. Cell Signal. 2025. PMID: 40818540
-
MiR-3682-3p promotes esophageal cancer progression by targeting FHL1 and activating the Wnt/β-catenin signaling pathway.Cell Signal. 2024 Jul;119:111155. doi: 10.1016/j.cellsig.2024.111155. Epub 2024 Mar 31. Cell Signal. 2024. PMID: 38565413
-
Functional mechanisms of circular RNA‑encoded peptides and future research strategies and directions in nasopharyngeal carcinoma (Review).Int J Oncol. 2025 Oct;67(4):82. doi: 10.3892/ijo.2025.5788. Epub 2025 Aug 24. Int J Oncol. 2025. PMID: 40849819 Free PMC article. Review.
-
Emerging Insights into Wnt/β-catenin Signaling in Head and Neck Cancer.J Dent Res. 2018 Jun;97(6):665-673. doi: 10.1177/0022034518771923. J Dent Res. 2018. PMID: 29771197 Free PMC article. Review.
References
-
- J. Yu, T. Pham, N. Wandrey, M. Daly, and S. Karam, “Multimodality Management of EBV‐Associated Nasopharyngeal Carcinoma,” Cancers 13, no. 23 (2021): 6078.
-
- J. Zhang, X. Luo, Q. Huang, and Y. Huang, “Clinicopathological and Prognostic Features of Nasopharyngeal Carcinoma in Children and Adolescents: A Retrospective Study of 196 Cases in South China,” International Journal of Cancer 148, no. 5 (2021): 1087–1096.
-
- A. W. M. Lee, W. T. Ng, J. Y. W. Chan, et al., “Management of Locally Recurrent Nasopharyngeal Carcinoma,” Cancer Treatment Reviews 79 (2019): 101890.
-
- X. R. Tang, Y. Q. Li, S. B. Liang, et al., “Development and Validation of a Gene Expression‐Based Signature to Predict Distant Metastasis in Locoregionally Advanced Nasopharyngeal Carcinoma: A Retrospective, Multicentre, Cohort Study,” Lancet Oncology 19, no. 3 (2018): 382–393.
-
- J. H. Yang, X. S. Sun, B. B. Xiao, et al., “Subdivision of De‐Novo Metastatic Nasopharyngeal Carcinoma Based on Tumor Burden and Pretreatment EBV DNA for Therapeutic Guidance of Locoregional Radiotherapy,” BMC Cancer 21, no. 1 (2021): 534.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous